| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5844817 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2013 | 61 Pages |
Abstract
In conclusion, our findings suggested the BDNF Val66Met as the best single candidate involved in AD response, with a selective effect on SSRI treatment. Our overall results supported no major effect of any single gene variant on AD efficacy.
Keywords
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Tomihisa Niitsu, Chiara Fabbri, Francesco Bentini, Alessandro Serretti,